Science & Research

Psilocybin therapy for hard-to-treat depression inside the NHS: the first publicly funded UK trial

Nature Medicine · 2026

Psilocybin therapy for hard-to-treat depression inside the NHS: the first publicly funded UK trial

Photo: Jaanus Jagomägi on Unsplash

The question

Most psilocybin trials take place in specialist research centres. This study asked whether psilocybin therapy can be delivered within an ordinary public health service, the UK's NHS. It also looked at how much it helps people with treatment-resistant depression, meaning depression that has not improved with at least two earlier treatments.

Who took part and what happened

The study was a double-blind, randomized, placebo-controlled feasibility trial at South London and Maudsley NHS Foundation Trust and King's College London. It ran from 2021 to 2024 and included 60 adults. On average, they had been ill for about 20 years.

  • 30 people received a single dose of psilocybin, 25 mg.
  • 30 people received a placebo.

Both groups had the same preparation, a supported dosing day of about six hours, and integration sessions. They were followed for six weeks.

What they found

  • The therapy was practical to deliver: every participant attended the dosing day, and 59 of 60 completed the depression assessments at every visit.
  • At week 3, depression scores (MADRS) were 10.4 points lower with psilocybin than with placebo (95% CI −14.9 to −6.0). At week 6 the gap was 12.9 points.
  • At week 3, 43% of the psilocybin group had responded (their score halved), compared with 3% on placebo. At week 6 it was 50% versus 3%.
  • At week 3, 40% of the psilocybin group were in remission, compared with 3% on placebo.
  • Most side effects were mild. The serious adverse events in people who received psilocybin were judged unrelated to the treatment.

What this study does not tell us

This was a small trial, mainly designed to test feasibility, with no formal hypothesis testing. Follow-up lasted only six weeks. All participants asked in the psilocybin group and 70% in the placebo group guessed their group, so expectations may explain part of the difference. Larger trials are needed, including on cost.

Why it matters

It is the first publicly funded randomized trial of psilocybin for depression in the UK. It shows that this kind of therapy can be delivered within a public health service, and the early results support a larger confirmatory trial.

This is a summary of published research for general information. It is not medical advice. The study took place in a clinical research setting with medical screening and professional support.

Source: Rucker JJ, Mantingh T, Kerr-Gaffney J, Bird C, Chu P, Modlin NL, et al., Young AH (2026). Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial. Nature Medicine, 32, 3430–3437. doi:10.1038/s41591-026-04541-0 · PubMed · Full text

More research

All research → · About MycoSpirit · Health & Safety

Made on
Tilda